ATE158789T1 - Substituierte beta-lactam-verbindungen als hypocholesterolemische mittel und verfahren zu deren herstellung - Google Patents
Substituierte beta-lactam-verbindungen als hypocholesterolemische mittel und verfahren zu deren herstellungInfo
- Publication number
- ATE158789T1 ATE158789T1 AT92916790T AT92916790T ATE158789T1 AT E158789 T1 ATE158789 T1 AT E158789T1 AT 92916790 T AT92916790 T AT 92916790T AT 92916790 T AT92916790 T AT 92916790T AT E158789 T1 ATE158789 T1 AT E158789T1
- Authority
- AT
- Austria
- Prior art keywords
- alkenylene
- optionally substituted
- sum
- phenyl
- heteroaryl
- Prior art date
Links
- 239000003529 anticholesteremic agent Substances 0.000 title abstract 3
- -1 BETA-LACTAM COMPOUNDS Chemical class 0.000 title abstract 2
- 125000004450 alkenylene group Chemical group 0.000 abstract 6
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000002947 alkylene group Chemical group 0.000 abstract 4
- 125000004419 alkynylene group Chemical group 0.000 abstract 4
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000002993 cycloalkylene group Chemical group 0.000 abstract 2
- 125000001624 naphthyl group Chemical group 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 abstract 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 abstract 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 abstract 1
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 125000005493 quinolyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
- C07D205/085—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a nitrogen atom directly attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- C07F7/1872—Preparation; Treatments not provided for in C07F7/20
- C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73442691A | 1991-07-23 | 1991-07-23 | |
US73465291A | 1991-07-23 | 1991-07-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE158789T1 true ATE158789T1 (de) | 1997-10-15 |
Family
ID=27112730
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT92916790T ATE158789T1 (de) | 1991-07-23 | 1992-07-21 | Substituierte beta-lactam-verbindungen als hypocholesterolemische mittel und verfahren zu deren herstellung |
Country Status (24)
Country | Link |
---|---|
US (2) | US5306817A (de) |
EP (2) | EP0596015B1 (de) |
JP (1) | JP2525125B2 (de) |
CN (1) | CN1069024A (de) |
AT (1) | ATE158789T1 (de) |
AU (1) | AU658441B2 (de) |
BG (1) | BG61118B2 (de) |
CZ (1) | CZ14294A3 (de) |
DE (1) | DE69222532T2 (de) |
EE (1) | EE9400342A (de) |
ES (1) | ES2107548T3 (de) |
FI (1) | FI940296A (de) |
HU (1) | HUT67341A (de) |
IE (1) | IE922374A1 (de) |
IL (1) | IL102582A0 (de) |
MX (1) | MX9204327A (de) |
MY (1) | MY131273A (de) |
NO (1) | NO940221L (de) |
NZ (1) | NZ243669A (de) |
OA (1) | OA09878A (de) |
SK (1) | SK7994A3 (de) |
TW (1) | TW223059B (de) |
WO (1) | WO1993002048A1 (de) |
YU (1) | YU72092A (de) |
Families Citing this family (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5688787A (en) * | 1991-07-23 | 1997-11-18 | Schering Corporation | Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof |
US5688785A (en) * | 1991-07-23 | 1997-11-18 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
AU4226593A (en) * | 1992-06-26 | 1994-01-24 | Pfizer Inc. | Steroidal glycosides for treating hypercholesterolemia |
CA2106840A1 (en) * | 1992-09-25 | 1994-03-26 | Marco Baroni | Heteroarylazetidines and -pyrrolidines, process for their preparation and pharmaceutical compositions containing them |
LT3300B (en) * | 1992-12-23 | 1995-06-26 | Schering Corp | Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor |
LT3595B (en) * | 1993-01-21 | 1995-12-27 | Schering Corp | Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents |
WO1995001961A1 (en) * | 1993-07-09 | 1995-01-19 | Schering Corporation | Process for the synthesis of azetidinones |
US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5627176A (en) * | 1994-03-25 | 1997-05-06 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
WO1995035277A1 (en) * | 1994-06-20 | 1995-12-28 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
US5633246A (en) * | 1994-11-18 | 1997-05-27 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5624920A (en) * | 1994-11-18 | 1997-04-29 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5656624A (en) * | 1994-12-21 | 1997-08-12 | Schering Corporation | 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents |
ATE232239T1 (de) * | 1995-09-27 | 2003-02-15 | Schering Corp | Stereoselektiver, mikrobieller reduktionsprozess |
WO1997016184A1 (en) | 1995-11-02 | 1997-05-09 | Warner-Lambert Company | Method and pharmaceutical composition for regulating lipid concentration |
WO1997016424A1 (en) * | 1995-11-02 | 1997-05-09 | Schering Corporation | Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone |
HUP9901359A3 (en) * | 1996-04-26 | 2000-03-28 | Smithkline Beecham Plc | Azetidinone derivatives for the treatment of atherosclerosis, process for their producing and pharmaceutical compositions containing them |
US5756470A (en) * | 1996-10-29 | 1998-05-26 | Schering Corporation | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
AU4343500A (en) | 1999-04-16 | 2000-11-02 | Schering Corporation | Use of azetidinone compounds |
DE10042447A1 (de) * | 2000-08-29 | 2002-03-28 | Aventis Pharma Gmbh | Protein aus dem Darm von Wirbeltieren, welches Cholesterin absorbiert, sowie Verwendung dieses Proteins zur Identifizierung von Inhibitoren des intestinalen Cholesterintransports |
US6584357B1 (en) * | 2000-10-17 | 2003-06-24 | Sony Corporation | Method and system for forming an acoustic signal from neural timing difference data |
US6982251B2 (en) * | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
US7071181B2 (en) | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
AU2005246926B2 (en) * | 2001-01-26 | 2008-02-28 | Merck Sharp & Dohme Corp. | The use of substituted azetidinone compounds for the treatment of sitosterolemia |
US20060287254A1 (en) * | 2001-01-26 | 2006-12-21 | Schering Corporation | Use of substituted azetidinone compounds for the treatment of sitosterolemia |
EP1911462A3 (de) | 2001-01-26 | 2011-11-30 | Schering Corporation | Zusammensetzungen enthaltend einen Sterolabsorptionshemmer |
CZ305202B6 (cs) * | 2001-01-26 | 2015-06-10 | Merck Sharp & Dohme Corp. | Farmaceutický prostředek |
CZ309209B6 (cs) * | 2001-01-26 | 2022-05-25 | Schering Corporation | Farmaceutický prostředek |
AR034204A1 (es) * | 2001-01-26 | 2004-02-04 | Schering Corp | Composiciones y combinaciones de acido nicotinico y derivados del mismo con inhibidor(es) de la absorcion de los esteroles, y el uso de los mismos para preparar medicamentos para el tratamiento para indicaciones vasculares |
TWI291957B (en) * | 2001-02-23 | 2008-01-01 | Kotobuki Pharmaceutical Co Ltd | Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same |
NZ527852A (en) | 2001-03-28 | 2005-03-24 | Schering Corp | Enantioselective synthesis of azetidinone intermediate compounds |
JP2004538285A (ja) | 2001-07-16 | 2004-12-24 | ユーロ−セルティック エス. ア. | アリール置換チアゾリジノンおよびその使用 |
US7056906B2 (en) | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
EP1429756B1 (de) | 2001-09-21 | 2006-11-22 | Schering Corporation | Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption |
MXPA04002572A (es) * | 2001-09-21 | 2004-05-31 | Schering Corp | Metodos para el tratamiento o prevencion de inflamacion vascular usando inhibidores de absorcion de esterol. |
US20030204096A1 (en) * | 2002-03-25 | 2003-10-30 | Schering Corporation | Enantioselective synthesis of azetidinone intermediate compounds |
GB0215579D0 (en) | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
US7135556B2 (en) * | 2002-07-19 | 2006-11-14 | Schering Corporation | NPC1L1 (NPC3) and methods of use thereof |
US20040132058A1 (en) | 2002-07-19 | 2004-07-08 | Schering Corporation | NPC1L1 (NPC3) and methods of use thereof |
AR040588A1 (es) | 2002-07-26 | 2005-04-13 | Schering Corp | Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa |
CN1678296A (zh) * | 2002-07-30 | 2005-10-05 | 卡里凯昂公司 | 依泽替米贝的组合物和治疗胆固醇有关的良性与恶性肿瘤的方法 |
ES2350977T3 (es) | 2002-11-05 | 2011-01-28 | Glaxo Group Limited | Agentes antibacterianos. |
JP2006508188A (ja) * | 2002-11-06 | 2006-03-09 | シェーリング コーポレイション | 脱髄の処置のためのコレステロール吸収インヒビター |
US7459442B2 (en) * | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
MXPA05009501A (es) | 2003-03-07 | 2005-10-18 | Schering Corp | Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia. |
CN100439361C (zh) | 2003-03-07 | 2008-12-03 | 先灵公司 | 取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途 |
EP1606287B1 (de) | 2003-03-07 | 2013-10-02 | Merck Sharp & Dohme Corp. | Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia |
EP1522541A1 (de) * | 2003-10-07 | 2005-04-13 | Lipideon Biotechnology AG | Neue hypocholesterolemische Verbindungen |
EP1918000A2 (de) | 2003-11-05 | 2008-05-07 | Schering Corporation | Verbindungen aus lipidverändernden Wirkstoffen und substituierten Azetidinonen und Behandlungen für Gefäßzustände |
BRPI0416361A (pt) * | 2003-11-10 | 2007-05-08 | Microbia Inc | métodos para regular a quantidade de isoforma 4 de apoe na corrente sanguìnea e/ou cérebro do paciente, para prevenir, tratar ou melhorar os sintomas do mal de alzheimer, para regular a produção de pelo menos um peptìdeos beta amilóide de um paciente ou regular um nìvel de pelo menos um peptìdeo beta amilóide na corrente sangüìnea e/ou cérebro de um paciente, para prevenir ou tratar um tumor associado com o colesterol, e para prevenir ou diminuir a incidência de xantomas em um paciente |
SI1682499T1 (sl) * | 2003-11-10 | 2008-02-29 | Microbia Inc | 4-biarilil-1-fenilazetidin-2-oni |
ATE485267T1 (de) | 2003-12-23 | 2010-11-15 | Astrazeneca Ab | Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung |
CA2550373C (en) * | 2003-12-23 | 2012-01-31 | Merck & Co., Inc. | Anti-hypercholesterolemic compounds |
GB0329778D0 (en) * | 2003-12-23 | 2004-01-28 | Astrazeneca Ab | Chemical compounds |
CA2553769C (en) * | 2004-01-16 | 2011-01-04 | Merck & Co., Inc. | Npc1l1 (npc3) and methods of identifying ligands thereof |
MXPA06013456A (es) | 2004-05-21 | 2007-03-01 | Sanofi Aventis Deutschland | Metodo para producir derivados de 1,4-difenilazetidinona. |
DE102004025072A1 (de) | 2004-05-21 | 2005-12-15 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung von Diphenyl-azetidinon-Derivaten |
JP2008514718A (ja) * | 2004-09-29 | 2008-05-08 | シェーリング コーポレイション | 置換アゼチドノンおよびcb1アンタゴニストの組み合わせ |
WO2006050634A1 (fr) * | 2004-11-15 | 2006-05-18 | Xiamen Mchem Pharma (Group) Ltd. | Procede de preparation de la 1-(4-fluorophenyl)-(3r)-[3-(4-fluorophenyl)-(3s)-hydroxypropyl]-(4s)-(4-hydroxyphenyl)-2-azetidinone |
KR101351209B1 (ko) | 2004-12-03 | 2014-02-06 | 머크 샤프 앤드 돔 코포레이션 | Cb1 길항제로서 치환된 피페라진 |
EP1831162B1 (de) | 2004-12-20 | 2012-10-31 | Merck Sharp & Dohme Corp. | Verfahren zur synthese von azetidinonen |
WO2006086562A2 (en) * | 2005-02-09 | 2006-08-17 | Microbia, Inc. | Phenylazetidinone derivatives |
US20080194494A1 (en) * | 2005-04-26 | 2008-08-14 | Microbia, Inc. | 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia |
TW200726746A (en) * | 2005-05-06 | 2007-07-16 | Microbia Inc | Processes for production of 4-biphenylylazetidin-2-ones |
KR20080017345A (ko) * | 2005-05-11 | 2008-02-26 | 마이크로비아 인코포레이티드 | 페놀성 4-비페닐일아제티딘-2-온의 제조방법 |
KR20080025077A (ko) * | 2005-05-25 | 2008-03-19 | 마이크로비아 인코포레이티드 | 4-(비페닐일)아제티딘-2-온 포스폰산의 제조방법 |
ES2337727T3 (es) * | 2005-06-20 | 2010-04-28 | Schering Corporation | Derivados de piperidina utiles como antagonistas de histamina h3. |
SA06270191B1 (ar) | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
AR054482A1 (es) * | 2005-06-22 | 2007-06-27 | Astrazeneca Ab | Derivados de azetidinona para el tratamiento de hiperlipidemias |
EP1922304A2 (de) * | 2005-09-08 | 2008-05-21 | Teva Pharmaceutical Industries Ltd | Verfahren zur herstellung von (3r,4s)-4-((4-benzyloxy)phenyl)-1-(4-fluorophenyl)-3-((s)-3-(4-fluorophenyl)-3-hydroxypropyl)-2-azetidinon, einem zwischenprodukt zur synthese von ezetimib |
TW200806623A (en) * | 2005-10-05 | 2008-02-01 | Merck & Co Inc | Anti-hypercholesterolemic compounds |
US7514509B2 (en) * | 2005-12-16 | 2009-04-07 | Fina Technology, Inc. | Catalyst compositions and methods of forming isotactic polyproyplene |
EP1973877A2 (de) | 2006-01-18 | 2008-10-01 | Schering Corporation | Cannabinoid-rezeptormodulatoren |
US7910698B2 (en) * | 2006-02-24 | 2011-03-22 | Schering Corporation | NPC1L1 orthologues |
AR060623A1 (es) | 2006-04-27 | 2008-07-02 | Astrazeneca Ab | Compuestos derivados de 2-azetidinona y un metodo de preparacion |
CA2661404A1 (en) * | 2006-09-05 | 2008-03-13 | Schering Corporation | Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis |
WO2008108486A1 (ja) * | 2007-03-06 | 2008-09-12 | Teijin Pharma Limited | 1-ビアリールアゼチジノン誘導体 |
US20100197564A1 (en) * | 2007-04-19 | 2010-08-05 | Schering Corporation | Diaryl morpholines as cb1 modulators |
US20090047716A1 (en) * | 2007-06-07 | 2009-02-19 | Nurit Perlman | Reduction processes for the preparation of ezetimibe |
CN101796033A (zh) | 2007-06-28 | 2010-08-04 | 英特维特国际股份有限公司 | 作为cb1拮抗剂的取代的哌嗪 |
CN101790521A (zh) * | 2007-06-28 | 2010-07-28 | 英特维特国际股份有限公司 | 作为cb1拮抗剂的取代哌嗪 |
WO2009032264A1 (en) * | 2007-08-30 | 2009-03-12 | Teva Pharmaceutical Industries Ltd. | Processes for preparing intermediates of ezetimibe by microbial reduction |
US20090312302A1 (en) * | 2008-06-17 | 2009-12-17 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders |
US9212175B2 (en) | 2009-03-06 | 2015-12-15 | Lipideon Biotechnology Ag | Pharmaceutical hypocholesterolemic compositions |
AU2010256360A1 (en) | 2009-06-05 | 2012-01-12 | Astrazeneca Ab | Aminopyrrolidinone derivatives and uses thereof |
CN101993403B (zh) | 2009-08-11 | 2012-07-11 | 浙江海正药业股份有限公司 | 氮杂环丁酮类化合物及医药应用 |
TW201427658A (zh) | 2012-12-10 | 2014-07-16 | Merck Sharp & Dohme | 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法 |
CN103254107B (zh) * | 2013-05-09 | 2015-10-21 | 东华大学 | 一种依泽替米贝类似物及其制备方法 |
CN103435525B (zh) * | 2013-07-25 | 2015-11-18 | 凯莱英医药集团(天津)股份有限公司 | 一种制备依折麦布的方法 |
CN103524486B (zh) * | 2013-09-18 | 2016-03-02 | 中国科学院昆明植物研究所 | N-喹啉基取代的β-内酰胺类化合物及其药物组合物和合成方法与应用 |
CN113801050B (zh) * | 2021-09-27 | 2023-11-14 | 山东大学 | 一种多取代β-内酰胺类化合物及其制备方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235913A (en) * | 1977-06-07 | 1980-11-25 | Pfizer Inc. | 9-Hydroxyhexahydrodibeno[b,d]pyrans, 1-substituted-9-hydroxyhexahydrodibenzo]b,d]pyrans |
CA1184175A (en) * | 1981-02-27 | 1985-03-19 | Walter Hunkeler | Imidazodiazepines |
US4680391A (en) * | 1983-12-01 | 1987-07-14 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
DK476885D0 (da) * | 1985-10-17 | 1985-10-17 | Ferrosan As | Heterocycliske forbindelser og fremgangsmaader til fremstilling heraf |
US4870169A (en) * | 1985-07-17 | 1989-09-26 | President And Fellows Of Harvard College | Intermediates for beta-lactam antibiotics |
US4845229A (en) * | 1985-09-25 | 1989-07-04 | University Of Notre Dame Du Lac | Process for intermediates to 1-carbapenems and 1-carbacephems |
US4745201A (en) * | 1985-09-25 | 1988-05-17 | University Of Notre Dame Du Lac | Process for intermediates to 1-carbapenems and 1-carbacephems |
US4803266A (en) * | 1986-10-17 | 1989-02-07 | Taisho Pharmaceutical Co., Ltd. | 3-Oxoalkylidene-2-azetidinone derivatives |
NZ228600A (en) * | 1988-04-11 | 1992-02-25 | Merck & Co Inc | 1-(benzylaminocarbonyl)-4-phenoxy-azetidin-2-one derivatives |
US4952689A (en) * | 1988-10-20 | 1990-08-28 | Taisho Pharmaceutical Co., Ltd. | 3-(substituted propylidene)-2-azetidinone derivates for blood platelet aggregation |
FR2640621B1 (fr) * | 1988-12-19 | 1992-10-30 | Centre Nat Rech Scient | N-aryl-azetidinones, leur procede de preparation et leur utilisation comme inhibiteurs des elastases |
US5120729A (en) * | 1990-06-20 | 1992-06-09 | Merck & Co., Inc. | Beta-lactams as antihypercholesterolemics |
IL99658A0 (en) * | 1990-10-15 | 1992-08-18 | Merck & Co Inc | Substituted azetidinones and pharmaceutical compositions containing them |
-
1992
- 1992-07-21 EP EP92916790A patent/EP0596015B1/de not_active Expired - Lifetime
- 1992-07-21 IL IL102582A patent/IL102582A0/xx unknown
- 1992-07-21 SK SK79-94A patent/SK7994A3/sk unknown
- 1992-07-21 MY MYPI92001303A patent/MY131273A/en unknown
- 1992-07-21 AU AU23980/92A patent/AU658441B2/en not_active Ceased
- 1992-07-21 TW TW081105745A patent/TW223059B/zh active
- 1992-07-21 EP EP19920112425 patent/EP0524595A1/de active Pending
- 1992-07-21 WO PCT/US1992/005972 patent/WO1993002048A1/en active IP Right Grant
- 1992-07-21 ES ES92916790T patent/ES2107548T3/es not_active Expired - Lifetime
- 1992-07-21 DE DE69222532T patent/DE69222532T2/de not_active Expired - Lifetime
- 1992-07-21 CZ CS94142A patent/CZ14294A3/cs unknown
- 1992-07-21 HU HU9400185A patent/HUT67341A/hu unknown
- 1992-07-21 AT AT92916790T patent/ATE158789T1/de not_active IP Right Cessation
- 1992-07-21 JP JP5502964A patent/JP2525125B2/ja not_active Expired - Fee Related
- 1992-07-22 YU YU72092A patent/YU72092A/sh unknown
- 1992-07-22 CN CN92108760A patent/CN1069024A/zh active Pending
- 1992-07-22 NZ NZ243669A patent/NZ243669A/en unknown
- 1992-07-22 IE IE237492A patent/IE922374A1/en not_active Application Discontinuation
- 1992-07-23 MX MX9204327A patent/MX9204327A/es not_active IP Right Cessation
- 1992-10-19 US US07/962,768 patent/US5306817A/en not_active Expired - Fee Related
-
1994
- 1994-01-07 US US08/179,008 patent/US6093812A/en not_active Expired - Fee Related
- 1994-01-21 FI FI940296A patent/FI940296A/fi not_active Application Discontinuation
- 1994-01-21 OA OA60459A patent/OA09878A/en unknown
- 1994-01-21 NO NO940221A patent/NO940221L/no unknown
- 1994-02-24 BG BG98565A patent/BG61118B2/bg unknown
- 1994-11-23 EE EE9400342A patent/EE9400342A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
HUT67341A (en) | 1995-03-28 |
NO940221D0 (no) | 1994-01-21 |
AU658441B2 (en) | 1995-04-13 |
YU72092A (sh) | 1995-12-04 |
NO940221L (no) | 1994-01-21 |
BG61118B2 (bg) | 1996-11-29 |
FI940296A0 (fi) | 1994-01-21 |
HU9400185D0 (en) | 1994-05-30 |
EP0596015B1 (de) | 1997-10-01 |
JP2525125B2 (ja) | 1996-08-14 |
FI940296A (fi) | 1994-01-21 |
IE922374A1 (en) | 1993-01-27 |
CZ14294A3 (en) | 1994-07-13 |
WO1993002048A1 (en) | 1993-02-04 |
DE69222532T2 (de) | 1998-02-26 |
MY131273A (en) | 2007-07-31 |
OA09878A (en) | 1994-09-15 |
JPH06508637A (ja) | 1994-09-29 |
EP0596015A1 (de) | 1994-05-11 |
AU2398092A (en) | 1993-02-23 |
US5306817A (en) | 1994-04-26 |
US6093812A (en) | 2000-07-25 |
ES2107548T3 (es) | 1997-12-01 |
CN1069024A (zh) | 1993-02-17 |
NZ243669A (en) | 1994-12-22 |
EE9400342A (et) | 1996-04-15 |
MX9204327A (es) | 1994-07-29 |
SK7994A3 (en) | 1994-07-06 |
DE69222532D1 (de) | 1997-11-06 |
IL102582A0 (en) | 1993-01-14 |
EP0524595A1 (de) | 1993-01-27 |
TW223059B (de) | 1994-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE158789T1 (de) | Substituierte beta-lactam-verbindungen als hypocholesterolemische mittel und verfahren zu deren herstellung | |
CA2324959A1 (en) | Phthalimido compounds as intermediates for producing substance p receptor antagonists | |
ZW3690A1 (en) | Treatment and compounds | |
HU9401974D0 (en) | New intermediates for producing 9-[(substituted glicyl)-amido]-6-demetyl-6-deoxy-tetracyclines and pharmaceutical compositions containing them | |
ATE122045T1 (de) | Dc-89-verbindungen und verfahren zu ihrer herstellung. | |
IL99106A0 (en) | Novel tricyclic compound or salts thereof,method for producing the same and antimicrobial agent containing the same | |
PH31092A (en) | Method of lowering cholesterol | |
ATE223925T1 (de) | 2,2'-disubstituierte 1,1'-diphosphino-ferrocene und 1',2-disubstituierte 1-phosphino-ferrocene, verfahren zu ihrer herstellung, ihre verwendung sowie sie enthaltende übergangsmetallkomplexe | |
DE59305012D1 (de) | 4-Amino-2-ureido-pyrimidin-5-carbonsäureamide, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung | |
CA2114007A1 (en) | Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof | |
ATE160566T1 (de) | Amphotere tricyclische verbindungen als antihistaminische und antiallergische mittel | |
ATE281452T1 (de) | 4-amino-2-ureido-pyrimidin-5-carbonsäureamide, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung | |
CA2056334A1 (en) | Process for producing benzylphthalazinone derivatives and salts thereof | |
HU9601701D0 (en) | Aromatic hydroxamic acid compounds, process for producing them and their use | |
PL311843A1 (en) | 1,2-bridge 1,4-dihydropyridine derivatives, method of obtaining them, their application and drugs containing such derivatives | |
DE3480542D1 (en) | Cephem compounds | |
ATE71618T1 (de) | 2-anilino-chinoline, verfahren zu ihrer herstellung und diese enthaltende fungizide. | |
CA2039909A1 (en) | Substituted 3-thia- and 3-oxa-alkylflavones, a process for their preparation, the use thereof, medicaments based on these compounds and intermediates | |
CA2168962A1 (en) | Novel substituted propane-2-ol derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |